View Older Stories View More Recent Stories
-
Cosmos Health reports record revenue of $65.3 million for 2025
-
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash P
-
Cosmos Health receives third order from Pharmalink for 60,000 units
-
Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3
-
Cosmos Health reports no Middle East conflict impact, targets $12M US revenue
-
Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months
-
Cosmos Health plans Q2 launch of liver supplement Liv18 in US
-
Cosmos Health Continues Expansion in the United States with Q2 Launch of Liv18 - a Clinically Proven, Patented Supplement for Liver Fat Reduction
-
Cosmos Health's C-Scrub Wash 4% passes European surgical disinfection test
-
Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
-
Cosmos Health projects $12M+ revenue from U.S. expansion
-
Cosmos Health buys $600,000 in bitcoin, digital assets reach $3.1 million
-
Cosmos Health expands C-Scrub to Superdrug stores across UK
-
Cosmos Health's C-Scrub now available at Tesco stores in UK
-
Cosmos Health purchases $500,000 in bitcoin, expanding crypto holdings
-
Cosmos Health expands robotic operations to support $40M revenue potential
-
Cosmos Health signs manufacturing deal for PathMuscle with Libytec
-
Cosmos Health (COSM) files for 74.66M share offering by selling stockholders
-
Cosmos Health reports Q3 revenue exceeds $17 million amid US expansion
-
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
-
Cosmos Health reports record quarterly revenue of $17 million
-
Cosmos Health is Forcing the Market to Reframe the Conversation
-
Cosmos Health CEO purchases 3.4 million shares year-to-date
-
Cosmos Health (COSM) Misses Q3 EPS by 2c
-
Cosmos Health reports Q3 revenue up 38% to $17.1 million
-
Cosmos Health (COSM) files $200M mixed shelf
-
Cosmos Health starts nanotechnology program for supplement formulas
-
Cosmos Health purchases additional $200,000 in Ethereum under digital facility
-
Cosmos Health buys additional $300,000 in ethereum, total reaches $1.8 million
-
Cosmos Health buys additional $500,000 in ethereum
-
Cosmos Health signs Kuwait distribution deal for nutraceuticals
-
Cosmos Health (COSM) CEO Greg Siokas issues letter to shareholders
-
Cosmos Health launches U.S. nutraceuticals operations with Sky Premium Life
-
Cosmos Health signs distribution deal for Oman nutraceuticals market
-
Cosmos Health (COSM) Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
-
Cosmos Health (COSM) Receives Nasdaq Extension to Regain Compliance
-
Cosmos Health (COSM) CEO Acquires $526K in Shares Past Week
-
Cosmos Health (COSM) Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBIT
-
Cosmos Health (COSM) Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
-
Cosmos Health (COSM) Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
-
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
-
Cosmos Health (COSM) will not Proceed with an Offering Under Its Form S-1
-
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
-
Cosmos Health (COSM) Enters Final Development Phase of CCX0722
-
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
-
Cosmos Health (COSM) Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies
-
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market
-
Cosmos Health (COSM) appoints Dimitris Moraitis as VP of Strategy and Operations
-
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
-
Cosmos Health (COSM) Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products
